Last reviewed · How we verify

Mycosis fungoides — Treatment Landscape & Competitive Intelligence

Mycosis fungoides (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Mycosis fungoides, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Poteligeo MOGAMULIZUMAB Kyowa Kirin Chemokine Receptor Type 4 Interaction [EPC] C-C chemokine receptor type 4 2018-01-01
Depo-Medrol METHYLPREDNISOLONE ACETATE Pfizer Corticosteroid Glucocorticoid receptor 1959-01-01
Cytoxan (Lyophilized) cyclophosphamide Baxter Alkylating agent Tumor cell DNA 1959-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Solu-Cortef hydrocortisone succinate Pfizer Corticosteroid Glucocorticoid receptor 1955-01-01
Trexall methotrexate Generic (originally Lederle Laboratories) Antifolate, DMARD Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 1953-12-07
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 4 drugs in Mycosis fungoides
  2. Pfizer · 3 drugs in Mycosis fungoides
  3. Generic (originally Schering) · 2 drugs in Mycosis fungoides
  4. Baxter · 2 drugs in Mycosis fungoides
  5. Generic (originally Merck/Upjohn) · 1 drug in Mycosis fungoides
  6. Generic (originally Upjohn/Pfizer) · 1 drug in Mycosis fungoides
  7. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in Mycosis fungoides
  8. Hannover Medical School · 1 drug in Mycosis fungoides
  9. Kyowa Kirin · 1 drug in Mycosis fungoides
  10. Kyowa Kirin Pharmaceutical Development Ltd · 1 drug in Mycosis fungoides
  11. Leiden University Medical Center · 1 drug in Mycosis fungoides
  12. Recordati · 1 drug in Mycosis fungoides

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Mycosis fungoides:

Cite this brief

Drug Landscape (2026). Mycosis fungoides — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mycosis-fungoides. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing